pert,cell,type,trend,WTCS,WTCS_Pval,WTCS_FDR,NCS,Tau,TauRefSize,NCSct,N_upset,N_downset,t_gn_sym,MOAss,PCIDss,pert_iname,canonical_smiles,inchi_key,compound_aliases,target,MOA,is_touchstone,pubchem_cid,chembl_id,molregno,PubChem_ID,DrugBank_ID,pref_name,max_phase,therapeutic_flag,molecule_type,first_approval,oral,parenteral,topical,natural_product,inorganic_flag,usan_year,availability_type,usan_stem,usan_stem_definition,indication_class,withdrawn_flag,withdrawn_year,withdrawn_country,withdrawn_reason,withdrawn_class,mechanism_of_action,action_type,direct_interaction,molecular_mechanism,disease_efficacy,mechanism_comment,selectivity_comment,NameAliasMer,MOAclue,mergeMOA,mergeTargets,Ntar,isLAD,Target_pathway,sig
BRD-K28936863,HUVEC,trt_cp,up,0.510385573152554,2.1324050321451356e-5,1.6067600119737743e-4,1.6126221569494101,NA,NA,0.8092958223619907,108,62,HRH1; PDE4A; PDE4B; PDE4C; PDE4D; PDE7A; PDE7B; PDE8A; PDE8B; PGD,Histamine receptor agonist; Histamine receptor ligand; Leukotriene receptor antagonist; Phosphodiesterase inhibitor,3827,ketotifen,CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,NA,HRH1,Histamine receptor ligand; Histamine receptor agonist; Phosphodiesterase inhibitor; Leukotriene receptor antagonist,1,3827,CHEMBL534,12957,3827,DB00920,KETOTIFEN,4,1,Small molecule,1999,0,0,1,0,0,1979,2,NA,NA,Anti-Asthmatic,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ketotifen,Histamine receptor agonist; Histamine receptor ligand; Leukotriene receptor antagonist; Phosphodiesterase inhibitor,Histamine receptor ligand; Histamine receptor agonist; Phosphodiesterase inhibitor; Leukotriene receptor antagonist,HRH1; PDE4A; PDE4B; PDE4C; PDE4D; PDE7A; PDE7B; PDE8A; PDE8B; PGD,10,FALSE,Amine ligand-binding receptors; Class A/1 (Rhodopsin-like receptors); DARPP-32 events; G alpha (i) signalling events; G alpha (q) signalling events; G alpha (s) signalling events; GPCR downstream signalling; GPCR ligand binding; Histamine receptors; Metabolism; Metabolism of carbohydrates; Opioid Signalling; Pentose phosphate pathway; Signal Transduction; Signaling by GPCR,TRUE
BRD-K79018442,HUVEC,trt_cp,up,0.4998348797734314,2.1759235021889136e-5,1.6067600119737743e-4,1.5792860228395478,NA,NA,1.0333414492840283,108,62,NA,NA,NA,KIN001-260,C1CC1COC2=CC=CC(=O)C2=C3C=C(C(=C(N3)N)C#N)C4CCNCC4,DWQVGCQPWXKRKO-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,KIN001-260,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K82967685,HUVEC,trt_cp,up,0.4785239162200484,2.2673122892808483e-5,1.6067600119737743e-4,1.5119515725339656,NA,NA,0.9058849034718303,108,62,NA,NA,NA,mirodenafil,CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1,MIJFNYMSCFYZNY-UHFFFAOYSA-N,NA,PDE5A,Phosphodiesterase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mirodenafil,NA,Phosphodiesterase inhibitor,PDE5A,1,FALSE,"Hemostasis; Nitric oxide stimulates guanylate cyclase; Platelet homeostasis; RHO GTPase cycle; RHOBTB GTPase Cycle; RHOBTB1 GTPase cycle; Signal Transduction; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; cGMP effects",TRUE
BRD-K30550578,HUVEC,trt_cp,up,0.45602571219553834,2.3674047703815382e-5,1.6067600119737743e-4,1.4408658988590772,NA,NA,1.030840131384877,108,62,DGAT1,NA,NA,PF-04620110,Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12,GEVVQZHMFVFGLN-HDJSIYSDSA-N,NA,DGAT1,Diacylglycerol O acyltransferase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PF-04620110,NA,Diacylglycerol O acyltransferase inhibitor,DGAT1,1,FALSE,Acyl chain remodeling of DAG and TAG; Glycerophospholipid biosynthesis; Immune System; Innate Immune System; Metabolism; Metabolism of lipids; Neutrophil degranulation; Phospholipid metabolism; Triglyceride biosynthesis; Triglyceride metabolism,TRUE
BRD-K86856088,HUVEC,trt_cp,up,0.43863764015550155,2.4413861694559614e-5,1.6067600119737743e-4,1.3859262772996437,NA,NA,1.1286341751604825,108,62,NA,NA,NA,UNC-0638,CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)C5CCCCC5,QOECJCJVIMVJGX-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,UNC-0638,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K66989831,HUVEC,trt_cp,up,0.42354168583871543,2.5066638745216286e-5,1.6067600119737743e-4,1.338228866377198,NA,NA,0.9951700341886084,108,62,NA,NA,167551,anacardic-acid,CCCCCCCCCCCCCCCc1cccc(O)c1C(O)=O,ADFWQBGTDJIESE-UHFFFAOYSA-N,NA,NA,NA,0,167551,CHEMBL33778,44946,167551,NA,ANACARDIC ACID,0,0,Small molecule,NA,0,0,0,-1,-1,NA,-1,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,anacardic-acid,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K49468759,HUVEC,trt_cp,up,0.41791535563198035,2.5327749565478957e-5,1.6067600119737743e-4,1.3204518263686968,NA,NA,1.066693094402282,108,62,NA,NA,44143370,KIN001-266,CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1,PHNZIIMWDVXPGG-UHFFFAOYSA-N,KIN-001-266,NA,NA,0,44143370,CHEMBL527026,501148,44143370,NA,NA,0,0,Small molecule,NA,0,0,0,-1,-1,NA,-1,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,KIN001-266,NA,NA,NA,0,FALSE,NA,TRUE
BRD-A32172948,HUVEC,trt_cp,up,0.4142896712321857,2.550182344565407e-5,1.6067600119737743e-4,1.3089960578188535,NA,NA,1.0320564000404437,108,62,NA,NA,NA,methiopril,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O,JHFOAISYWJRTIM-UHFFFAOYSA-N,NA,ACE,Angiotensin converting enzyme inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,methiopril,NA,Angiotensin converting enzyme inhibitor,ACE,1,FALSE,Metabolism of Angiotensinogen to Angiotensins; Metabolism of proteins; Peptide hormone metabolism,TRUE
BRD-K91308639,HUVEC,trt_cp,up,0.4115942017871072,2.5588860385741625e-5,1.6067600119737743e-4,1.3004794108382884,NA,NA,0.835089201889732,108,62,NA,NA,NA,ARN-509,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F,HJBWBFZLDZWPHF-UHFFFAOYSA-N,NA,AR,Androgen receptor antagonist,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ARN-509,NA,Androgen receptor antagonist,AR,1,FALSE,"Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3; Cellular responses to stimuli; Cellular responses to stress; Deubiquitination; Gene expression (Transcription); Generic Transcription Pathway; HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand; Metabolism of proteins; Nuclear Receptor transcription pathway; Post-translational protein modification; RHO GTPase Effectors; RHO GTPases activate PKNs; RNA Polymerase II Transcription; RUNX2 regulates bone development; RUNX2 regulates osteoblast differentiation; SUMO E3 ligases SUMOylate target proteins; SUMOylation; SUMOylation of intracellular receptors; Signal Transduction; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Transcriptional regulation by RUNX2; Ub-specific processing proteases",TRUE
BRD-K31519811,HUVEC,trt_cp,up,0.4110345899335939,2.5632378855785405e-5,1.6067600119737743e-4,1.2987112525639608,NA,NA,1.0774874141024935,108,62,NA,NA,NA,PF-02545920,Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1,AZEXWHKOMMASPA-UHFFFAOYSA-N,NA,PDE10A,Phosphodiesterase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PF-02545920,NA,Phosphodiesterase inhibitor,PDE10A,1,FALSE,G alpha (s) signalling events; GPCR downstream signalling; Hemostasis; Nitric oxide stimulates guanylate cyclase; Platelet homeostasis; Signal Transduction; Signaling by GPCR; cGMP effects,TRUE
BRD-K33483813,HUVEC,trt_cp,up,0.4089743393487751,2.571941579587296e-5,1.6067600119737743e-4,1.2922016529265243,NA,NA,0.920127833626623,108,62,NA,Interleukin receptor agonist,2018,actarit,CC(=O)Nc1ccc(CC(O)=O)cc1,MROJXXOCABQVEF-UHFFFAOYSA-N,NA,NA,NA,1,2018,CHEMBL1885632,1226203,2018,NA,ACTARIT,0,0,Small molecule,NA,0,0,0,0,0,NA,NA,-arit,antirheumatics (lobenzarit type),NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,actarit,Interleukin receptor agonist,Interleukin receptor agonist,NA,0,FALSE,NA,TRUE
BRD-K84794093,HUVEC,trt_cp,up,0.3919887741459713,2.6459229786617192e-5,1.6067600119737743e-4,1.238533798200225,NA,NA,0.9766590762632101,108,62,NA,NA,NA,dideoxyadenosine,Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1,WVXRAFOPTSTNLL-NKWVEPMBSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,dideoxyadenosine,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K31476763,HUVEC,trt_cp,up,0.39168442179067464,2.6459229786617192e-5,1.6067600119737743e-4,1.2375721617875037,NA,NA,0.8227770812852302,108,62,NA,NA,NA,AZD-9668,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,QNQZWEGMKJBHEM-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,AZD-9668,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K29530284,HUVEC,trt_cp,up,0.3909672990013952,2.650274825666097e-5,1.6067600119737743e-4,1.2353063295224922,NA,NA,1.044474701193868,108,62,FGF1; IL3; PPID; S100A12; S100A13; S100A9,Histamine receptor modulator,2161,amlexanox,CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O,SGRYPYWGNKJSDL-UHFFFAOYSA-N,NA,NA,NA,1,2161,CHEMBL1096,150549,2161,DB01025,AMLEXANOX,4,1,Small molecule,1996,0,0,1,0,0,1995,1,-xanox,antiallergic respiratory tract drugs (xanoxic acid derivatives),Anti-Allergic,0,NA,NA,NA,NA,Phosphodiesterase 4 inhibitor,INHIBITOR,1,1,1,NA,NA,amlexanox,Histamine receptor modulator,Histamine receptor modulator; Phosphodiesterase 4 inhibitor,FGF1; IL3; PPID; S100A12; S100A13; S100A9,6,FALSE,"Activated point mutants of FGFR2; Adaptive Immune System; Advanced glycosylation endproduct receptor signaling; Antigen processing-Cross presentation; Antimicrobial peptides; Class I MHC mediated antigen processing & presentation; Constitutive Signaling by Aberrant PI3K in Cancer; Cytokine Signaling in Immune system; DDX58/IFIH1-mediated induction of interferon-alpha/beta; Disease; Diseases associated with the TLR signaling cascade; Diseases of Immune System; Diseases of signal transduction by growth factor receptors and second messengers; Downstream signaling of activated FGFR1; Downstream signaling of activated FGFR2; Downstream signaling of activated FGFR3; Downstream signaling of activated FGFR4; ER-Phagosome pathway; ESR-mediated signaling; FGFR1 ligand binding and activation; FGFR1 mutant receptor activation; FGFR1b ligand binding and activation; FGFR1c ligand binding and activation; FGFR2 ligand binding and activation; FGFR2 mutant receptor activation; FGFR2b ligand binding and activation; FGFR2c ligand binding and activation; FGFR3 ligand binding and activation; FGFR3 mutant receptor activation; FGFR3b ligand binding and activation; FGFR3c ligand binding and activation; FGFR4 ligand binding and activation; FRS-mediated FGFR1 signaling; FRS-mediated FGFR2 signaling; FRS-mediated FGFR3 signaling; FRS-mediated FGFR4 signaling; Gene expression (Transcription); Generic Transcription Pathway; IGF1R signaling cascade; IRAK4 deficiency (TLR2/4); IRS-mediated signalling; IRS-related events triggered by IGF1R; Immune System; Innate Immune System; Insulin receptor signalling cascade; Interleukin receptor SHC signaling; Interleukin-1 family signaling; Interleukin-1 signaling; Interleukin-2 family signaling; Interleukin-3, Interleukin-5 and GM-CSF signaling; Intracellular signaling by second messengers; MAPK family signaling cascades; MAPK1/MAPK3 signaling; Metal sequestration by antimicrobial proteins; MyD88 cascade initiated on plasma membrane; MyD88 deficiency (TLR2/4); MyD88 dependent cascade initiated on endosome; MyD88-independent TLR4 cascade; MyD88:MAL(TIRAP) cascade initiated on plasma membrane; Negative regulation of FGFR1 signaling; Negative regulation of FGFR2 signaling; Negative regulation of FGFR3 signaling; Negative regulation of FGFR4 signaling; Negative regulation of the PI3K/AKT network; Neutrophil degranulation; PI-3K cascade:FGFR1; PI-3K cascade:FGFR2; PI-3K cascade:FGFR3; PI-3K cascade:FGFR4; PI3K Cascade; PI3K/AKT Signaling in Cancer; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; Phospholipase C-mediated cascade: FGFR1; Phospholipase C-mediated cascade; FGFR2; Phospholipase C-mediated cascade; FGFR3; Phospholipase C-mediated cascade; FGFR4; RAF/MAP kinase cascade; RHO GTPase Effectors; RHO GTPases Activate NADPH Oxidases; RNA Polymerase II Transcription; RUNX1 regulates transcription of genes involved in interleukin signaling; Regulation of TLR by endogenous ligand; SHC-mediated cascade:FGFR1; SHC-mediated cascade:FGFR2; SHC-mediated cascade:FGFR3; SHC-mediated cascade:FGFR4; Signal Transduction; Signaling by FGFR; Signaling by FGFR in disease; Signaling by FGFR1; Signaling by FGFR1 in disease; Signaling by FGFR2; Signaling by FGFR2 IIIa TM; Signaling by FGFR2 in disease; Signaling by FGFR3; Signaling by FGFR3 in disease; Signaling by FGFR3 point mutants in cancer; Signaling by FGFR4; Signaling by Insulin receptor; Signaling by Interleukins; Signaling by Nuclear Receptors; Signaling by Receptor Tyrosine Kinases; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R); Signaling by activated point mutants of FGFR1; Signaling by activated point mutants of FGFR3; TAK1 activates NFkB by phosphorylation and activation of IKKs complex; TRAF6 mediated NF-kB activation; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation; TRIF(TICAM1)-mediated TLR4 signaling; Toll Like Receptor 10 (TLR10) Cascade; Toll Like Receptor 2 (TLR2) Cascade; Toll Like Receptor 3 (TLR3) Cascade; Toll Like Receptor 4 (TLR4) Cascade; Toll Like Receptor 5 (TLR5) Cascade; Toll Like Receptor 7/8 (TLR7/8) Cascade; Toll Like Receptor 9 (TLR9) Cascade; Toll Like Receptor TLR1:TLR2 Cascade; Toll Like Receptor TLR6:TLR2 Cascade; Toll-like Receptor Cascades; Transcriptional regulation by RUNX1",TRUE
BRD-K55591206,HUVEC,trt_cp,up,0.3721740255995423,2.7329599187492756e-5,1.6067600119737743e-4,1.1759268119898183,NA,NA,0.9007424481626863,108,62,NA,NA,NA,BRD-K55591206,Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1,WMBWREPUVVBILR-WIYYLYMNSA-N,epigallocatechin-gallate-(-),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,epigallocatechin-gallate-(-),NA,NA,NA,0,TRUE,NA,TRUE
BRD-K71480163,HUVEC,trt_cp,up,0.3675815580205484,2.750367306766787e-5,1.6067600119737743e-4,1.161416380342598,NA,NA,0.9926842416798725,108,62,NA,NA,NA,GDC-0068,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1,GRZXWCHAXNAUHY-AHRSYUTCSA-N,NA,AKT3; AKT1; AKT2,Akt inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,GDC-0068,NA,Akt inhibitor,AKT3; AKT1; AKT2,3,FALSE,"AKT phosphorylates targets in the cytosol; AKT phosphorylates targets in the nucleus; AKT-mediated inactivation of FOXO1A; Activation of AKT2; Activation of BAD and translocation to mitochondria; Activation of BH3-only proteins; Adaptive Immune System; Apoptosis; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA; CD28 co-stimulation; CD28 dependent PI3K/Akt signaling; CTLA4 inhibitory signaling; Cell Cycle; Cell Cycle, Mitotic; Constitutive Signaling by AKT1 E17K in Cancer; Costimulation by the CD28 family; Cyclin A:Cdk2-associated events at S phase entry; Cyclin E associated events during G1/S transition; Cytokine Signaling in Immune system; Deactivation of the beta-catenin transactivating complex; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; Downregulation of ERBB2 signaling; Downregulation of ERBB2:ERBB3 signaling; ESR-mediated signaling; Estrogen-dependent nuclear events downstream of ESR-membrane signaling; Extra-nuclear estrogen signaling; FLT3 Signaling; FOXO-mediated transcription; G beta:gamma signalling through PI3Kgamma; G-protein beta:gamma signalling; G1/S Transition; GPCR downstream signalling; Gene expression (Transcription); Generic Transcription Pathway; Hemostasis; IGF1R signaling cascade; IRS-mediated signalling; IRS-related events triggered by IGF1R; Immune System; Inhibition of TSC complex formation by PKB; Insulin receptor signalling cascade; Integrin signaling; Interleukin-4 and Interleukin-13 signaling; Intracellular signaling by second messengers; Intrinsic Pathway for Apoptosis; KSRP (KHSRP) binds and destabilizes mRNA; MTOR signalling; Membrane Trafficking; Metabolism; Metabolism of RNA; Metabolism of cofactors; Metabolism of nitric oxide: NOS3 activation and regulation; Metabolism of vitamins and cofactors; Mitotic G1 phase and G1/S transition; Negative regulation of NOTCH4 signaling; Negative regulation of the PI3K/AKT network; PDE3B signalling; PI3K Cascade; PI3K/AKT Signaling in Cancer; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; PKB-mediated events; PTEN Regulation; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1; Platelet Aggregation (Plug Formation); Platelet activation, signaling and aggregation; Programmed Cell Death; RAB GEFs exchange GTP for GDP on RABs; RNA Polymerase II Transcription; RUNX2 regulates genes involved in cell migration; Rab regulation of trafficking; Regulation of PTEN stability and activity; Regulation of TP53 Activity; Regulation of TP53 Activity through Acetylation; Regulation of TP53 Activity through Association with Co-factors; Regulation of TP53 Degradation; Regulation of TP53 Expression and Degradation; Regulation of beta-cell development; Regulation of gene expression in beta cells; Regulation of localization of FOXO transcription factors; Regulation of mRNA stability by proteins that bind AU-rich elements; S Phase; Signal Transduction; Signaling by ERBB2; Signaling by GPCR; Signaling by Insulin receptor; Signaling by Interleukins; Signaling by NOTCH; Signaling by NOTCH4; Signaling by Non-Receptor Tyrosine Kinases; Signaling by Nuclear Receptors; Signaling by PTK6; Signaling by Receptor Tyrosine Kinases; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R); Signaling by VEGF; Signaling by WNT; TCF dependent signaling in response to WNT; TP53 Regulates Metabolic Genes; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation; Transcriptional Regulation by TP53; Transcriptional regulation by RUNX2; Translocation of SLC2A4 (GLUT4) to the plasma membrane; VEGFA-VEGFR2 Pathway; VEGFR2 mediated vascular permeability; Vesicle-mediated transport; eNOS activation",TRUE
BRD-K72166146,HUVEC,trt_cp,up,0.36628719918278657,2.7590710007755428e-5,1.6067600119737743e-4,1.1573267041240383,NA,NA,0.9189464828345526,108,62,NA,NA,NA,BRD-K72166146,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,LUZRJRNZXALNLM-JGRZULCMSA-N,dihydroergotamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,dihydroergotamine,Serotonin receptor agonist,Serotonin receptor agonist,HTR1B; HTR1D; HTR1E; HTR1F; HTR2B; HTR7,6,FALSE,"ADORA2B mediated anti-inflammatory cytokines production; Amine ligand-binding receptors; Anti-inflammatory response favouring Leishmania parasite infection; Class A/1 (Rhodopsin-like receptors); Disease; G alpha (i) signalling events; G alpha (q) signalling events; G alpha (s) signalling events; GPCR downstream signalling; GPCR ligand binding; Infectious disease; Leishmania infection; Leishmania parasite growth and survival; RHOBTB3 ATPase cycle; Serotonin receptors; Signal Transduction; Signaling by GPCR; Signaling by Rho GTPases, Miro GTPases and RHOBTB3",TRUE
BRD-K71035033,HUVEC,trt_cp,up,0.3630164704074974,2.776478388793054e-5,1.6067600119737743e-4,1.1469924588595728,NA,NA,0.8056548802345374,108,62,DDR1; DDR2; FGFR3; KIT; LYN; PDGFRA; PDGFRB,KIT inhibitor; PDGFR receptor inhibitor; SRC inhibitor,10074640,masitinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1,WJEOLQLKVOPQFV-UHFFFAOYSA-N,NA,FGFR3; KIT; LYN; PDGFRA; PDGFRB,KIT inhibitor; Src inhibitor; PDGFR inhibitor,1,10074640,CHEMBL1908391,1248752,10074640,DB11526,MASITINIB,3,1,Small molecule,NA,0,0,0,0,0,NA,NA,-tinib,tyrosine kinase inhibitors,NA,0,NA,NA,NA,NA,Fibroblast growth factor receptor 3 inhibitor,INHIBITOR,1,1,1,"Approved veterinary - 2012. Not recommended for approval (Negative opinion) in EU, phase 3 trials in US.",NA,masitinib,KIT inhibitor; PDGFR receptor inhibitor; SRC inhibitor,KIT inhibitor; Src inhibitor; PDGFR inhibitor; PDGFR receptor inhibitor; SRC inhibitor; Fibroblast growth factor receptor 3 inhibitor,FGFR3; KIT; LYN; PDGFRA; PDGFRB; DDR1; DDR2,7,FALSE,"Adaptive Immune System; Anti-inflammatory response favouring Leishmania parasite infection; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers; Axon guidance; C-type lectin receptors (CLRs); CD209 (DC-SIGN) signaling; CD22 mediated BCR regulation; CD28 co-stimulation; CTLA4 inhibitory signaling; Cell Cycle; Cell Cycle, Mitotic; Cell surface interactions at the vascular wall; Constitutive Signaling by Aberrant PI3K in Cancer; Costimulation by the CD28 family; Cyclin D associated events in G1; Cytokine Signaling in Immune system; Dasatinib-resistant KIT mutants; Dectin-2 family; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; Downstream signal transduction; Downstream signaling of activated FGFR3; Drug resistance of KIT mutants; Drug resistance of PDGFR mutants; EPH-Ephrin signaling; EPH-ephrin mediated repulsion of cells; EPHA-mediated growth cone collapse; EPHB-mediated forward signaling; Erythropoietin activates Phosphoinositide-3-kinase (PI3K); Erythropoietin activates Phospholipase C gamma (PLCG); Erythropoietin activates RAS; Erythropoietin activates STAT5; Extracellular matrix organization; FCERI mediated Ca+2 mobilization; FCERI mediated MAPK activation; FCERI mediated NF-kB activation; FCGR activation; FCGR3A-mediated IL10 synthesis; FCGR3A-mediated phagocytosis; FGFR3 ligand binding and activation; FGFR3 mutant receptor activation; FGFR3b ligand binding and activation; FGFR3c ligand binding and activation; FRS-mediated FGFR3 signaling; Fc epsilon receptor (FCERI) signaling; Fcgamma receptor (FCGR) dependent phagocytosis; G1 Phase; GPVI-mediated activation cascade; Gene expression (Transcription); Generic Transcription Pathway; Growth hormone receptor signaling; Hemostasis; IGF1R signaling cascade; IRS-mediated signalling; IRS-related events triggered by IGF1R; Imatinib-resistant KIT mutants; Imatinib-resistant PDGFR mutants; Immune System; Inactivation of CSF3 (G-CSF) signaling; Infectious disease; Innate Immune System; Insulin receptor signalling cascade; Interleukin-3, Interleukin-5 and GM-CSF signaling; Intracellular signaling by second messengers; KIT mutants bind TKIs; Leishmania infection; Leishmania parasite growth and survival; Leishmania phagocytosis; MAPK family signaling cascades; MAPK1/MAPK3 signaling; Masitinib-resistant KIT mutants; Mitotic G1 phase and G1/S transition; Negative regulation of FGFR3 signaling; Negative regulation of the PI3K/AKT network; Nervous system development; Nilotinib-resistant KIT mutants; Non-integrin membrane-ECM interactions; PDGFR mutants bind TKIs; PECAM1 interactions; PI-3K cascade:FGFR3; PI3K Cascade; PI3K/AKT Signaling in Cancer; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; Parasite infection; Phospholipase C-mediated cascade; FGFR3; Platelet Adhesion to exposed collagen; Platelet activation, signaling and aggregation; RAF/MAP kinase cascade; RNA Polymerase II Transcription; Regorafenib-resistant KIT mutants; Regorafenib-resistant PDGFR mutants; Regulation of KIT signaling; Regulation of signaling by CBL; Role of LAT2/NTAL/LAB on calcium mobilization; SHC-mediated cascade:FGFR3; Signal Transduction; Signaling by CSF3 (G-CSF); Signaling by Erythropoietin; Signaling by FGFR; Signaling by FGFR in disease; Signaling by FGFR3; Signaling by FGFR3 fusions in cancer; Signaling by FGFR3 in disease; Signaling by FGFR3 point mutants in cancer; Signaling by Insulin receptor; Signaling by Interleukins; Signaling by KIT in disease; Signaling by PDGF; Signaling by PDGFR in disease; Signaling by PDGFRA extracellular domain mutants; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants; Signaling by Receptor Tyrosine Kinases; Signaling by SCF-KIT; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R); Signaling by activated point mutants of FGFR3; Signaling by extracellular domain mutants of KIT; Signaling by juxtamembrane domain KIT mutants; Signaling by kinase domain mutants of KIT; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants; Signaling by the B Cell Receptor (BCR); Sorafenib-resistant KIT mutants; Sorafenib-resistant PDGFR mutants; Sunitinib-resistant KIT mutants; Sunitinib-resistant PDGFR mutants; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors; Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors; t(4;14) translocations of FGFR3",TRUE
BRD-K91263825,HUVEC,trt_cp,up,0.3618659796210195,2.780830235797432e-5,1.6067600119737743e-4,1.143357350362715,NA,NA,1.0384737028804292,108,62,ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; ADRB1; ADRB2; ADRB3; CHRM1; CHRM4; CHRM5; HRH1; HTR6; KCNJ10; PGRMC1; PIK3CD; SIGMAR1; SLC6A2; SLC6A4,Tricyclic antidepressant,441358,nortriptyline,CNCCC=C1c2ccccc2CCc2ccccc12,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NA,KCNJ10; SLC6A2; SLC6A4,Tricyclic antidepressant,1,441358,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,nortriptyline,Tricyclic antidepressant,Tricyclic antidepressant,KCNJ10; SLC6A2; SLC6A4; ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; ADRB1; ADRB2; ADRB3; CHRM1; CHRM4; CHRM5; HRH1; HTR6; PGRMC1; PIK3CD; SIGMAR1,19,FALSE,"ADORA2B mediated anti-inflammatory cytokines production; Activation of G protein gated Potassium channels; Activation of GABAB receptors; Adaptive Immune System; Adrenaline signalling through Alpha-2 adrenergic receptor; Adrenaline,noradrenaline inhibits insulin secretion; Adrenoceptors; Amine ligand-binding receptors; Anti-inflammatory response favouring Leishmania parasite infection; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers; Axon guidance; Cargo recognition for clathrin-mediated endocytosis; Class A/1 (Rhodopsin-like receptors); Clathrin-mediated endocytosis; Constitutive Signaling by Aberrant PI3K in Cancer; Cytokine Signaling in Immune system; Defective SLC6A2 causes orthostatic intolerance (OI); Deubiquitination; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; Disorders of transmembrane transporters; Erythropoietin activates Phosphoinositide-3-kinase (PI3K); G alpha (12/13) signalling events; G alpha (i) signalling events; G alpha (q) signalling events; G alpha (s) signalling events; G alpha (z) signalling events; G protein gated Potassium channels; GABA B receptor activation; GABA receptor activation; GPCR downstream signalling; GPCR ligand binding; Hemostasis; Histamine receptors; Immune System; Infectious disease; Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits; Innate Immune System; Integration of energy metabolism; Interleukin receptor SHC signaling; Interleukin-2 family signaling; Interleukin-3, Interleukin-5 and GM-CSF signaling; Intracellular signaling by second messengers; Inwardly rectifying K+ channels; Leishmania infection; Leishmania parasite growth and survival; Membrane Trafficking; Metabolism; Metabolism of lipids; Metabolism of proteins; Muscarinic acetylcholine receptors; Na+/Cl- dependent neurotransmitter transporters; Negative regulation of the PI3K/AKT network; Nervous system development; Neuronal System; Neurotransmitter clearance; Neurotransmitter receptors and postsynaptic signal transmission; Neutrophil degranulation; PI Metabolism; PI3K/AKT Signaling in Cancer; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; Phospholipid metabolism; Platelet Aggregation (Plug Formation); Platelet activation, signaling and aggregation; Post-translational protein modification; Potassium Channels; Potassium transport channels; Potential therapeutics for SARS; RET signaling; Regulation of insulin secretion; Regulation of signaling by CBL; SARS-CoV Infections; SLC transporter disorders; SLC-mediated transmembrane transport; Serotonin clearance from the synaptic cleft; Serotonin receptors; Signal Transduction; Signaling by Erythropoietin; Signaling by GPCR; Signaling by Interleukins; Signaling by the B Cell Receptor (BCR); Surfactant metabolism; Synthesis of PIPs at the plasma membrane; Transmission across Chemical Synapses; Transport of bile salts and organic acids, metal ions and amine compounds; Transport of small molecules; Ub-specific processing proteases; Vesicle-mediated transport",TRUE
BRD-K30632436,HUVEC,trt_cp,up,0.3577395947974813,2.798237623814943e-5,1.6067600119737743e-4,1.130319561003907,NA,NA,0.8265531077423499,108,62,NA,NA,NA,CTB,CCOC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)Cl)C(F)(F)F,YDXZSNHARVUYNM-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,CTB,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K02501528,HUVEC,trt_cp,up,0.351789733076909,2.8656912523827993e-5,1.6067600119737743e-4,1.1115202858164945,NA,NA,1.0544644243211616,108,62,NA,NA,NA,S-18986,O=S1(=O)N[C@H]2CCCN2c2ccccc12,MNTIJYGEITVWHU-SNVBAGLBSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,S-18986,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K94335714,HUVEC,trt_cp,up,0.34479130722843676,3.0397651325579124e-5,1.6067600119737743e-4,1.089407951180342,NA,NA,0.9513520215112374,108,62,NA,NA,NA,MC1568,CN1C=C(C=C1C=CC(=O)NO)C=CC(=O)C2=CC(=CC=C2)F,QRDAPCMJAOQZSU-UHFFFAOYSA-N,NA,HDAC2,HDAC inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,MC1568,NA,HDAC inhibitor,HDAC2,1,FALSE,"Chromatin modifying enzymes; Chromatin organization; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants; Constitutive Signaling by NOTCH1 PEST Domain Mutants; Death Receptor Signalling; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; EGR2 and SOX10-mediated initiation of Schwann cell myelination; ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression; Epigenetic regulation of gene expression; FOXO-mediated transcription; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes; Factors involved in megakaryocyte development and platelet production; Gene expression (Transcription); Generic Transcription Pathway; HDACs deacetylate histones; Hemostasis; Infectious disease; Intracellular signaling by second messengers; MECP2 regulates neuronal receptors and channels; Metabolism of proteins; NOTCH1 Intracellular Domain Regulates Transcription; Negative epigenetic regulation of rRNA expression; Nervous system development; NoRC negatively regulates rRNA expression; Notch-HLH transcription pathway; PIP3 activates AKT signaling; PTEN Regulation; Positive epigenetic regulation of rRNA expression; Post-translational protein modification; Potential therapeutics for SARS; RNA Polymerase I Promoter Clearance; RNA Polymerase I Transcription; RNA Polymerase I Transcription Initiation; RNA Polymerase II Transcription; Regulation of MECP2 expression and activity; Regulation of PTEN gene transcription; Regulation of TP53 Activity; Regulation of TP53 Activity through Acetylation; SARS-CoV Infections; STAT3 nuclear events downstream of ALK signaling; SUMO E3 ligases SUMOylate target proteins; SUMOylation; SUMOylation of chromatin organization proteins; Signal Transduction; Signaling by ALK; Signaling by NOTCH; Signaling by NOTCH1; Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer; Signaling by NOTCH1 PEST Domain Mutants in Cancer; Signaling by NOTCH1 in Cancer; Signaling by Receptor Tyrosine Kinases; Transcriptional Regulation by MECP2; Transcriptional Regulation by TP53; p75 NTR receptor-mediated signalling; p75NTR negatively regulates cell cycle via SC1",TRUE
BRD-K32847255,HUVEC,trt_cp,up,0.3353043808676986,3.9057826864291e-5,1.76730255782915e-4,1.0594329118073131,NA,NA,0.891970280593597,108,62,KDM6B; UTY,NA,NA,GSK-J1,C1CN(CCC2=CC=CC=C21)C3=CC(=NC(=N3)C4=CC=CC=N4)NCCC(=O)[O-],AVZCPICCWKMZDT-UHFFFAOYSA-M,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,GSK-J1,NA,NA,KDM6B; UTY,2,FALSE,Cellular Senescence; Cellular responses to stimuli; Cellular responses to stress; Chromatin modifying enzymes; Chromatin organization; HDMs demethylate histones; Oxidative Stress Induced Senescence,TRUE
BRD-K41783120,HUVEC,trt_cp,up,0.33493027235336326,3.9057826864291e-5,1.76730255782915e-4,1.0582508727547706,NA,NA,1.12738491556591,108,62,NA,NA,NA,STA-5326,Cc1cccc(C=NNc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1,HSKAZIJJKRAJAV-KOEQRZSOSA-N,NA,IL12A,Interleukin synthesis inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,STA-5326,NA,Interleukin synthesis inhibitor,IL12A,1,FALSE,Cytokine Signaling in Immune system; Immune System; Interleukin-10 signaling; Interleukin-12 family signaling; Interleukin-12 signaling; Interleukin-35 Signalling; Interleukin-4 and Interleukin-13 signaling; Signaling by Interleukins,TRUE
BRD-K46839850,HUVEC,trt_cp,up,0.3343909006947679,4.0711528725954576e-5,1.81179115218464e-4,1.0565466657135942,NA,NA,0.8765998089875044,108,62,NA,NA,NA,cinepazide,COc1cc(cc(OC)c1OC)C=CC(=O)N1CCN(CC(=O)N2CCCC2)CC1,RCUDFXMNPQNBDU-VOTSOKGWSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,cinepazide,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K82941592,HUVEC,trt_cp,up,0.3337163753651433,4.0711528725954576e-5,1.81179115218464e-4,1.0544154250414541,NA,NA,0.922579451244289,108,62,APOB; CRP; HMGCR; SLCO1B1,HMGCR inhibitor,446157,rosuvastatin,CC(C)c1nc(nc(-c2ccc(F)cc2)c1C=C[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O,BPRHUIZQVSMCRT-VEUZHWNKSA-N,NA,HMGCR,HMGCR inhibitor,1,446157,CHEMBL1496,418845,446157,DB01098,ROSUVASTATIN,4,1,Small molecule,2003,1,0,0,0,0,2000,1,-stat-,enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors),NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,rosuvastatin,HMGCR inhibitor,HMGCR inhibitor,HMGCR; APOB; CRP; SLCO1B1,4,FALSE,"Activation of gene expression by SREBF (SREBP); Bile acid and bile salt metabolism; Binding and Uptake of Ligands by Scavenger Receptors; Cargo recognition for clathrin-mediated endocytosis; Cell surface interactions at the vascular wall; Cellular responses to stimuli; Cellular responses to stress; Cholesterol biosynthesis; Chylomicron assembly; Chylomicron clearance; Chylomicron remodeling; Classical antibody-mediated complement activation; Clathrin-mediated endocytosis; Complement cascade; Creation of C4 and C2 activators; Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR); Developmental Biology; Disease; Disorders of transmembrane transporters; EGR2 and SOX10-mediated initiation of Schwann cell myelination; Heme degradation; Heme signaling; Hemostasis; Immune System; Initial triggering of complement; Innate Immune System; LDL clearance; LDL remodeling; Membrane Trafficking; Metabolism; Metabolism of fat-soluble vitamins; Metabolism of lipids; Metabolism of porphyrins; Metabolism of proteins; Metabolism of steroids; Metabolism of vitamins and cofactors; Nervous system development; PPARA activates gene expression; Plasma lipoprotein assembly; Plasma lipoprotein assembly, remodeling, and clearance; Plasma lipoprotein clearance; Plasma lipoprotein remodeling; Platelet homeostasis; Platelet sensitization by LDL; Post-translational protein modification; Post-translational protein phosphorylation; Recycling of bile acids and salts; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs); Regulation of TLR by endogenous ligand; Regulation of cholesterol biosynthesis by SREBP (SREBF); Regulation of lipid metabolism by PPARalpha; Retinoid metabolism and transport; SLC transporter disorders; SLC-mediated transmembrane transport; Scavenging by Class A Receptors; Scavenging by Class B Receptors; Scavenging by Class F Receptors; Scavenging by Class H Receptors; Sensory Perception; Toll-like Receptor Cascades; Transport of organic anions; Transport of small molecules; Transport of vitamins, nucleosides, and related molecules; VLDL assembly; VLDL clearance; Vesicle-mediated transport; Visual phototransduction",TRUE
BRD-K89375097,HUVEC,trt_cp,up,0.3319470307531494,4.3779580864040944e-5,1.8866766476257783e-4,1.0488249764185509,NA,NA,0.857558976265655,108,62,ADCY10; CHRM1; CHRM4; CHRM5,Acetylcholine receptor antagonist,185248,pirenzepine,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,RMHMFHUVIITRHF-UHFFFAOYSA-N,NA,CHRM1,Acetylcholine receptor antagonist,1,185248,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,pirenzepine,Acetylcholine receptor antagonist,Acetylcholine receptor antagonist,CHRM1; ADCY10; CHRM4; CHRM5,4,FALSE,Amine ligand-binding receptors; Class A/1 (Rhodopsin-like receptors); G alpha (i) signalling events; G alpha (q) signalling events; GPCR downstream signalling; GPCR ligand binding; Hedgehog 'off' state; Muscarinic acetylcholine receptors; Signal Transduction; Signaling by GPCR; Signaling by Hedgehog,TRUE
BRD-K02943813,HUVEC,trt_cp,up,0.32962314191546843,4.802263169330933e-5,2.0078339116578805e-4,1.0414823812766392,NA,NA,1.035707640270189,108,62,NA,NA,NA,dasabuvir,COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1,NBRBXGKOEOGLOI-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,dasabuvir,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K02265150,HUVEC,trt_cp,up,0.3293318073726104,5.026383290056391e-5,2.0702673138785278e-4,1.0405618761455955,NA,NA,0.8331106443053453,108,62,ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; CHRM1; CHRM4; CHRM5; DRD1; DRD3; DRD4; GABRA2; GABRA3; GABRA4; GABRA5; GABRA6; GABRB1; GABRB2; GABRB3; GABRD; GABRE; GABRG1; GABRG2; GABRG3; GABRP; GABRQ; HRH1; HRH4; HTR1B; HTR2B; HTR3A; HTR6; HTR7; SLC6A2; SLC6A3; SLC6A4,Norepinephrine reuptake inhibitor,2170,amoxapine,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1,QWGDMFLQWFTERH-UHFFFAOYSA-N,NA,DRD1; DRD2; DRD3; DRD4; HTR2A; HTR6; SLC6A2; SLC6A4,Norepinephrine reputake inhibitor,1,2170,CHEMBL1113,155045,2170,DB00543,AMOXAPINE,4,1,Small molecule,1980,1,0,0,0,0,1971,1,-pine,tricyclic compounds,Antidepressant,0,NA,NA,NA,NA,Dopamine receptor antagonist,ANTAGONIST,1,1,1,NA,NA,amoxapine,Norepinephrine reuptake inhibitor,Norepinephrine reputake inhibitor; Norepinephrine reuptake inhibitor; Dopamine receptor antagonist,DRD1; DRD2; DRD3; DRD4; HTR2A; HTR6; SLC6A2; SLC6A4; ADRA1A; ADRA1B; ADRA1D; ADRA2B; ADRA2C; CHRM1; CHRM4; CHRM5; GABRA2; GABRA3; GABRA4; GABRA5; GABRA6; GABRB1; GABRB2; GABRB3; GABRD; GABRE; GABRG1; GABRG2; GABRG3; GABRP; GABRQ; HRH1; HRH4; HTR1B; HTR2B; HTR3A; HTR7; SLC6A3,38,TRUE,"ADORA2B mediated anti-inflammatory cytokines production; Adrenaline signalling through Alpha-2 adrenergic receptor; Adrenaline,noradrenaline inhibits insulin secretion; Adrenoceptors; Amine ligand-binding receptors; Anti-inflammatory response favouring Leishmania parasite infection; Class A/1 (Rhodopsin-like receptors); Defective SLC6A2 causes orthostatic intolerance (OI); Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS); Disease; Disorders of transmembrane transporters; Dopamine clearance from the synaptic cleft; Dopamine receptors; G alpha (12/13) signalling events; G alpha (i) signalling events; G alpha (q) signalling events; G alpha (s) signalling events; G alpha (z) signalling events; GABA receptor activation; GPCR downstream signalling; GPCR ligand binding; Hemostasis; Histamine receptors; Infectious disease; Integration of energy metabolism; Leishmania infection; Leishmania parasite growth and survival; Metabolism; Metabolism of proteins; Muscarinic acetylcholine receptors; Na+/Cl- dependent neurotransmitter transporters; Neuronal System; Neurotransmitter clearance; Neurotransmitter receptors and postsynaptic signal transmission; Platelet Aggregation (Plug Formation); Platelet activation, signaling and aggregation; RHOBTB3 ATPase cycle; Regulation of insulin secretion; SLC transporter disorders; SLC-mediated transmembrane transport; Serotonin clearance from the synaptic cleft; Serotonin receptors; Signal Transduction; Signaling by ERBB4; Signaling by GPCR; Signaling by Receptor Tyrosine Kinases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Surfactant metabolism; Transmission across Chemical Synapses; Transport of bile salts and organic acids, metal ions and amine compounds; Transport of small molecules",TRUE
BRD-K26325692,HUVEC,trt_cp,up,0.3290918313050291,5.026383290056391e-5,2.0702673138785278e-4,1.0398036440479899,NA,NA,0.9636805540645577,108,62,NA,NA,NA,API-001,Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1,DGPGXHRHNRYVDH-UHFFFAOYSA-N,NA,SIGMAR1,Sigma receptor antagonist,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,API-001,NA,Sigma receptor antagonist,SIGMAR1,1,FALSE,Disease; Infectious disease; Potential therapeutics for SARS; SARS-CoV Infections,TRUE
BRD-A30984645,HUVEC,trt_cp,up,0.32862306540116326,5.026383290056391e-5,2.0702673138785278e-4,1.0383225240423297,NA,NA,0.8981836212794202,108,62,BTK,NA,NA,GDC-0834,CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1,CDOOFZZILLRUQH-UHFFFAOYSA-N,NA,BTK,BTK inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,GDC-0834,NA,BTK inhibitor,BTK,1,FALSE,"Adaptive Immune System; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers; Antigen processing-Cross presentation; Class I MHC mediated antigen processing & presentation; DAP12 interactions; DAP12 signaling; Disease; Diseases associated with the TLR signaling cascade; Diseases of Immune System; ER-Phagosome pathway; FCERI mediated Ca+2 mobilization; FCGR3A-mediated phagocytosis; Fc epsilon receptor (FCERI) signaling; Fcgamma receptor (FCGR) dependent phagocytosis; G alpha (12/13) signalling events; G alpha (q) signalling events; G beta:gamma signalling through BTK; G-protein beta:gamma signalling; GPCR downstream signalling; IRAK4 deficiency (TLR2/4); Immune System; Infectious disease; Innate Immune System; Leishmania infection; Leishmania phagocytosis; MyD88 deficiency (TLR2/4); MyD88:MAL(TIRAP) cascade initiated on plasma membrane; Parasite infection; RHO GTPase Effectors; RHO GTPases Activate WASPs and WAVEs; Regulation of actin dynamics for phagocytic cup formation; Signal Transduction; Signaling by GPCR; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Signaling by the B Cell Receptor (BCR); Toll Like Receptor 2 (TLR2) Cascade; Toll Like Receptor 4 (TLR4) Cascade; Toll Like Receptor TLR1:TLR2 Cascade; Toll Like Receptor TLR6:TLR2 Cascade; Toll-like Receptor Cascades",TRUE
BRD-K19477839,HUVEC,trt_cp,up,0.3277867140413219,5.3136051923453277e-5,2.1577626608363393e-4,1.0356799753402883,NA,NA,1.0278939562881673,108,62,MET,NA,NA,SGX-523,Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1,BCZUAADEACICHN-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,SGX-523,NA,NA,MET,1,FALSE,"Axon guidance; Constitutive Signaling by Aberrant PI3K in Cancer; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; Gene expression (Transcription); Generic Transcription Pathway; Infectious disease; InlB-mediated entry of Listeria monocytogenes into host cell; Intracellular signaling by second messengers; Listeria monocytogenes entry into host cells; MAPK family signaling cascades; MAPK1/MAPK3 signaling; MECP2 regulates neuronal receptors and channels; MET Receptor Activation; MET activates PI3K/AKT signaling; MET activates PTK2 signaling; MET activates PTPN11; MET activates RAP1 and RAC1; MET activates RAS signaling; MET activates STAT3; MET interacts with TNS proteins; MET promotes cell motility; MET receptor recycling; Negative regulation of MET activity; Negative regulation of the PI3K/AKT network; Nervous system development; PI3K/AKT Signaling in Cancer; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; RAF/MAP kinase cascade; RNA Polymerase II Transcription; Sema4D in semaphorin signaling; Sema4D mediated inhibition of cell attachment and migration; Semaphorin interactions; Signal Transduction; Signaling by MET; Signaling by Receptor Tyrosine Kinases; Transcriptional Regulation by MECP2",TRUE
BRD-K83405785,HUVEC,trt_cp,up,0.32585350623676906,5.9402711609757345e-5,2.3401639846033334e-4,1.029571782037815,NA,NA,0.9137116584363281,108,62,NA,NA,NA,pimavanserin,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,RKEWSXXUOLRFBX-UHFFFAOYSA-N,NA,HTR2A,Serotonin receptor inverse agonist,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,pimavanserin,NA,Serotonin receptor inverse agonist,HTR2A,1,FALSE,Amine ligand-binding receptors; Class A/1 (Rhodopsin-like receptors); G alpha (q) signalling events; GPCR downstream signalling; GPCR ligand binding; Serotonin receptors; Signal Transduction; Signaling by GPCR,TRUE
BRD-K00610438,HUVEC,trt_cp,up,0.32276859744887293,7.195779021738738e-5,2.715455892554045e-4,1.0198246564817361,NA,NA,1.007635597716905,108,62,NA,Serotonin receptor antagonist,3033677,altanserin,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,SMYALUSCZJXWHG-UHFFFAOYSA-N,NA,HTR2A,Serotonin receptor antagonist,1,3033677,CHEMBL62919,101048,3033677,NA,ALTANSERIN,0,0,Small molecule,NA,0,0,0,1,0,1984,NA,-anserin,serotonin 5-HT2 receptor antagonists,Serotonin Antagonist,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,altanserin,Serotonin receptor antagonist,Serotonin receptor antagonist,HTR2A,1,FALSE,Amine ligand-binding receptors; Class A/1 (Rhodopsin-like receptors); G alpha (q) signalling events; GPCR downstream signalling; GPCR ligand binding; Serotonin receptors; Signal Transduction; Signaling by GPCR,TRUE
BRD-K46937689,HUVEC,trt_cp,up,0.3225986644801192,7.195779021738738e-5,2.715455892554045e-4,1.01928773364335,NA,NA,0.918295340334406,108,62,NA,Cyclooxygenase inhibitor,2206,phenazone,Cc1cc(=O)n(-c2ccccc2)n1C,VEQOALNAAJBPNY-UHFFFAOYSA-N,NA,NA,NA,1,2206,CHEMBL277474,26820,2206,DB01435,ANTIPYRINE,4,1,Small molecule,NA,0,0,0,0,0,NA,-1,NA,NA,Analgesic,0,NA,NA,NA,NA,Cyclooxygenase-1 inhibitor,INHIBITOR,1,1,1,"Antipyrine inhibits a brain COX isoform, COX-3. COX-3 is a COX-1 variant that retains intron 1 in its mRNA.",IC50 uM values for Antipyrine inhibition of COX enzymes: COX-1 : >1000 COX-2 : > 1000 COX-3 : 863,phenazone,Cyclooxygenase inhibitor,Cyclooxygenase inhibitor; Cyclooxygenase-1 inhibitor,NA,0,FALSE,NA,TRUE
BRD-K30020243,HUVEC,trt_cp,up,0.3217642289687687,7.741935820788155e-5,2.881869560284655e-4,1.0166512382858548,NA,NA,0.8806882633106161,108,62,ACE2; AGT; CMA1; CPA3; CTSG; CTSZ; ENPEP; REN,Antihypertensive; Peptidase inhibitor; Protease inhibitor; Renin inhibitor,5493444,aliskiren,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC,UXOWGYHJODZGMF-QORCZRPOSA-N,NA,REN,Renin inhibitor; Protease inhibitor; Peptidase inhibitor; Anti-hypertensive agent,1,5493444,CHEMBL1639,480746,5493444,DB09026,ALISKIREN,4,1,Small molecule,2007,1,0,0,0,0,2005,1,-kiren,renin inhibitors,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,aliskiren,Antihypertensive; Peptidase inhibitor; Protease inhibitor; Renin inhibitor,Renin inhibitor; Protease inhibitor; Peptidase inhibitor; Anti-hypertensive agent; Antihypertensive,REN; ACE2; AGT; CMA1; CPA3; CTSG; CTSZ; ENPEP,8,FALSE,Activation of Matrix Metalloproteinases; Antimicrobial peptides; Asparagine N-linked glycosylation; Attachment and Entry; COPII-mediated vesicle transport; Cargo concentration in the ER; Cell recruitment (pro-inflammatory response); Class A/1 (Rhodopsin-like receptors); Cytokine Signaling in Immune system; Degradation of the extracellular matrix; Disease; ER to Golgi Anterograde Transport; Extracellular matrix organization; G alpha (i) signalling events; G alpha (q) signalling events; GPCR downstream signalling; GPCR ligand binding; Immune System; Infection with Mycobacterium tuberculosis; Infectious disease; Innate Immune System; Interleukin-1 family signaling; Interleukin-1 processing; Leishmania infection; Lysosome Vesicle Biogenesis; Membrane Trafficking; Metabolism; Metabolism of Angiotensinogen to Angiotensins; Metabolism of lipids; Metabolism of proteins; Neutrophil degranulation; PPARA activates gene expression; Peptide hormone metabolism; Peptide ligand-binding receptors; Post-translational protein modification; Potential therapeutics for SARS; Purinergic signaling in leishmaniasis infection; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs); Regulation of lipid metabolism by PPARalpha; Response of Mtb to phagocytosis; SARS-CoV Infections; SARS-CoV-1 Infection; SARS-CoV-2 Infection; Signal Transduction; Signaling by GPCR; Signaling by Interleukins; Signaling by Receptor Tyrosine Kinases; Signaling by SCF-KIT; Suppression of apoptosis; Transport to the Golgi and subsequent modification; Vesicle-mediated transport; trans-Golgi Network Vesicle Budding,TRUE
BRD-A91877226,HUVEC,trt_cp,up,0.3125925718154453,1.55447974996376e-4,5.118953321268725e-4,0.9876723283804761,NA,NA,1.0000516311725116,108,62,CES2; CES5A; DPYD; TYMP; TYMS,DNA synthesis inhibitor; Thymidylate synthase inhibitor,60953,capecitabine,CCCCCOC(=O)Nc1nc(=O)n(cc1F)C1O[C@H](C)[C@@H](O)[C@H]1O,GAGWJHPBXLXJQN-LXGADPQPSA-N,NA,TYMS,DNA synthesis inhibitor; Thymidylate synthase inhibitor,1,60953,CHEMBL1773,598447,60953,DB01101,CAPECITABINE,4,1,Small molecule,1998,1,0,0,1,0,1995,1,-citabine,"nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives",Antineoplastic,0,NA,NA,NA,NA,DNA inhibitor,INHIBITOR,1,1,1,NA,NA,capecitabine,DNA synthesis inhibitor; Thymidylate synthase inhibitor,DNA synthesis inhibitor; Thymidylate synthase inhibitor; DNA inhibitor,TYMS; CES2; CES5A; DPYD; TYMP,5,TRUE,"Biological oxidations; Cell Cycle; Cell Cycle, Mitotic; G1/S Transition; G1/S-Specific Transcription; Interconversion of nucleotide di- and triphosphates; Metabolism; Metabolism of nucleotides; Mitotic G1 phase and G1/S transition; Nucleobase catabolism; Nucleotide salvage; Phase I - Functionalization of compounds; Pyrimidine catabolism; Pyrimidine salvage",TRUE
BRD-K49555808,HUVEC,trt_cp,up,0.31041997987081,2.0020672143640197e-4,6.347927228777223e-4,0.9808077732436845,NA,NA,0.8897433626574327,108,62,NA,NA,NA,BMS-707035,Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O,VNIWZCGZPBJWBI-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,BMS-707035,NA,NA,NA,0,FALSE,NA,TRUE
BRD-A70083328,HUVEC,trt_cp,up,0.3095231199141383,2.0020672143640197e-4,6.347927228777223e-4,0.9779740406425139,NA,NA,0.9926244309449082,108,62,NA,Acetylcholinesterase inhibitor; Antiprotozoal; Microtubule inhibitor,71815,secnidazole,CC(O)Cn1c(C)ncc1[N+]([O-])=O,KPQZUUQMTUIKBP-UHFFFAOYSA-N,NA,NA,NA,1,71815,CHEMBL498847,497784,71815,DB12834,SECNIDAZOLE,4,1,Small molecule,2017,1,0,0,0,0,2015,1,-nidazole,antiprotozoal substances (metronidazole type),NA,0,NA,NA,NA,NA,DNA inhibitor,INHIBITOR,1,1,1,Enters bacterial cell as an inactive prodrug where the nitro group is reduced by bacterial enzymes to radical anions. It is believed that these radical anions interfere with bacterial DNA synthesis,NA,secnidazole,Acetylcholinesterase inhibitor; Microtubule inhibitor; Antiprotozoal,Acetylcholinesterase inhibitor; Microtubule inhibitor; Antiprotozoal; DNA inhibitor,NA,0,FALSE,NA,TRUE
BRD-K83452553,HUVEC,trt_cp,up,0.30104009849214197,4.5709625010482513e-4,0.0013008958515330032,0.9511709548529028,NA,NA,0.9969615809051897,108,62,NA,NA,NA,daminozide,CN(C)NC(=O)CCC(=O)O,NOQGZXFMHARMLW-UHFFFAOYSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,daminozide,NA,NA,NA,0,FALSE,NA,TRUE
BRD-A82395837,HUVEC,trt_cp,up,0.2950206164663309,7.895120835342255e-4,0.002105674170215585,0.9321517062714383,NA,NA,0.8562093214704359,108,62,NA,NA,NA,ginkgolide-b,C[C@H]1C(=O)O[C@H]2[C@@H](O)C34[C@@H]5C[C@@H](C(C)(C)C)C33[C@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O,SQOJOAFXDQDRGF-DJCNAJSISA-N,NA,GLRA1; GLRB; PTAFR,Reducing agent; Immunosuppressant; Protease inhibitor; Peptidase inhibitor; GABA receptor antagonist; Glycine receptor antagonist; Platelet activating factor receptor antagonist,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ginkgolide-b,NA,Reducing agent; Immunosuppressant; Protease inhibitor; Peptidase inhibitor; GABA receptor antagonist; Glycine receptor antagonist; Platelet activating factor receptor antagonist,GLRA1; GLRB; PTAFR,3,FALSE,Class A/1 (Rhodopsin-like receptors); Cytokine Signaling in Immune system; G alpha (q) signalling events; GPCR downstream signalling; GPCR ligand binding; Immune System; Innate Immune System; Interferon Signaling; Interferon gamma signaling; Interleukin-10 signaling; Neuronal System; Neurotransmitter receptors and postsynaptic signal transmission; Neutrophil degranulation; Signal Transduction; Signaling by GPCR; Signaling by Interleukins; Transmission across Chemical Synapses,TRUE
BRD-A06935312,HUVEC,trt_cp,up,0.29278610464752713,9.442420037748791e-4,0.0024671861493340483,0.9250915081417956,NA,NA,0.9834020555944731,108,62,NA,NA,NA,fusidic-acid,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)C2=C(/CCC=C(C)C)C(O)=O,IECPWNUMDGFDKC-FRVBXGIOSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,fusidic-acid,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K46018455,HUVEC,trt_cp,up,0.28611072572110385,0.001746048055096472,0.004267853363875915,0.9039998775608393,NA,NA,0.9328767549928363,108,62,APOA1; APOA2; APOB; APOE; CETP; CRAT; HBE1; HBG1; HBG2; HSD11B1; LPL; NR1I2; PPARA; PPARD; PPARG; RXRA; RXRB; RXRG; SERPINE1; UCP3,PPAR receptor agonist,39042,bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,IIBYAHWJQTYFKB-UHFFFAOYSA-N,NA,PPARA; PPARD; PPARG,PPAR receptor agonist,1,39042,CHEMBL264374,57488,39042,DB01393,BEZAFIBRATE,4,1,Small molecule,NA,0,0,0,0,0,1978,-1,-fibrate,antihyperlipidemics (clofibrate type),Antihyperlipoproteinemic,0,NA,NA,NA,NA,Peroxisome proliferator-activated receptor agonist,AGONIST,1,1,1,"Bezafibrate is a peroxisome proliferator-activated receptor agonist that acts on all three receptor subtypes (alpha, delta and gamma). Bezafibrate simultaneously targets atherogenic dyslipidemia and insulin resistance without development of overweight; it reduces plasma triglycerides and glucose levels, increases HDL-C and decreases the prevalence of small, dense LDL particles.",NA,bezafibrate,PPAR receptor agonist,PPAR receptor agonist; Peroxisome proliferator-activated receptor agonist,PPARA; PPARD; PPARG; APOA1; APOA2; APOB; APOE; CETP; CRAT; HBE1; HBG1; HBG2; HSD11B1; LPL; NR1I2; RXRA; RXRB; RXRG; SERPINE1; UCP3,20,TRUE,"ABC transporter disorders; ABC transporters in lipid homeostasis; ABC-family proteins mediated transport; Activation of HOX genes during differentiation; Activation of anterior HOX genes in hindbrain development during early embryogenesis; Activation of gene expression by SREBF (SREBP); Amyloid fiber formation; Assembly of active LPL and LIPC lipase complexes; BMAL1:CLOCK,NPAS2 activates circadian gene expression; Beta-oxidation of pristanoyl-CoA; Bile acid and bile salt metabolism; Binding and Uptake of Ligands by Scavenger Receptors; Biological oxidations; Cargo recognition for clathrin-mediated endocytosis; Carnitine metabolism; Cell surface interactions at the vascular wall; Cellular response to chemical stress; Cellular responses to stimuli; Cellular responses to stress; Chylomicron assembly; Chylomicron clearance; Chylomicron remodeling; Circadian Clock; Clathrin-mediated endocytosis; Cytochrome P450 - arranged by substrate type; Cytoprotection by HMOX1; Defective ABCA1 causes TGD; Developmental Biology; Disease; Disorders of transmembrane transporters; Dissolution of Fibrin Clot; ECM proteoglycans; Endogenous sterols; Extracellular matrix organization; Factors involved in megakaryocyte development and platelet production; Fatty acid metabolism; Gene expression (Transcription); Generic Transcription Pathway; Glucocorticoid biosynthesis; HDL assembly; HDL clearance; HDL remodeling; Heme signaling; Hemostasis; Immune System; Innate Immune System; Intracellular signaling by second messengers; LDL clearance; LDL remodeling; MECP2 regulates transcription factors; Membrane Trafficking; Metabolism; Metabolism of fat-soluble vitamins; Metabolism of lipids; Metabolism of proteins; Metabolism of steroid hormones; Metabolism of steroids; Metabolism of vitamins and cofactors; Mitochondrial Uncoupling; Mitochondrial biogenesis; NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis; NR1H2 & NR1H3 regulate gene expression linked to lipogenesis; NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose; NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis; NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake; NR1H2 and NR1H3-mediated signaling; NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux; Nuclear Receptor transcription pathway; Nuclear signaling by ERBB4; Organelle biogenesis and maintenance; PIP3 activates AKT signaling; PPARA activates gene expression; PTEN Regulation; Peroxisomal lipid metabolism; Peroxisomal protein import; Phase I - Functionalization of compounds; Plasma lipoprotein assembly; Plasma lipoprotein assembly, remodeling, and clearance; Plasma lipoprotein clearance; Plasma lipoprotein remodeling; Platelet activation, signaling and aggregation; Platelet degranulation; Platelet homeostasis; Platelet sensitization by LDL; Post-translational protein modification; Post-translational protein phosphorylation; Protein localization; Pyruvate metabolism; Pyruvate metabolism and Citric Acid (TCA) cycle; RNA Polymerase II Transcription; RORA activates gene expression; Recycling of bile acids and salts; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs); Regulation of PTEN gene transcription; Regulation of TLR by endogenous ligand; Regulation of cholesterol biosynthesis by SREBP (SREBF); Regulation of lipid metabolism by PPARalpha; Regulation of pyruvate dehydrogenase (PDH) complex; Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.; Response to elevated platelet cytosolic Ca2+; Retinoid metabolism and transport; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription; SUMO E3 ligases SUMOylate target proteins; SUMOylation; SUMOylation of intracellular receptors; Scavenging by Class A Receptors; Scavenging by Class B Receptors; Scavenging by Class F Receptors; Scavenging by Class H Receptors; Scavenging of heme from plasma; Sensory Perception; Signal Transduction; Signaling by ERBB4; Signaling by Nuclear Receptors; Signaling by Receptor Tyrosine Kinases; Signaling by Retinoic Acid; Signaling by TGF-beta Receptor Complex; Signaling by TGFB family members; Synthesis of bile acids and bile salts; Synthesis of bile acids and bile salts via 27-hydroxycholesterol; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol; The citric acid (TCA) cycle and respiratory electron transport; The fatty acid cycling model; The proton buffering model; Toll-like Receptor Cascades; Transcriptional Regulation by MECP2; Transcriptional activation of mitochondrial biogenesis; Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer; Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors; Transcriptional regulation of granulopoiesis; Transcriptional regulation of white adipocyte differentiation; Transport of small molecules; VLDL assembly; VLDL clearance; Vesicle-mediated transport; Visual phototransduction",TRUE
BRD-K98251413,HUVEC,trt_cp,up,0.28587439241937973,0.001746048055096472,0.004267853363875915,0.9032531552026205,NA,NA,0.9334861852143816,108,62,NA,NA,NA,IOX2,OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,CAOSCCRYLYQBES-UHFFFAOYSA-N,IOX-2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,IOX2,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K68756823,HUVEC,trt_cp,up,0.28398598071394066,0.002071022230148386,0.004973631578016416,0.8972865003482846,NA,NA,0.8910696808394841,108,62,MAPK3,NA,53338808,FR-180204,Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1,XVECMUKVOMUNLE-UHFFFAOYSA-N,NA,MAPK1; MAPK3,MAP kinase inhibitor,1,53338808,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FR-180204,NA,MAP kinase inhibitor,MAPK1; MAPK3,2,FALSE,"Activation of NMDA receptors and postsynaptic events; Activation of the AP-1 family of transcription factors; Advanced glycosylation endproduct receptor signaling; Antiviral mechanism by IFN-stimulated genes; Apoptosis; Apoptotic factor-mediated response; Axon guidance; CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling; Ca-dependent events; Cell Cycle; Cell Cycle, Mitotic; Cellular Senescence; Cellular response to heat stress; Cellular responses to stimuli; Cellular responses to stress; Cytochrome c-mediated apoptotic response; Cytokine Signaling in Immune system; Developmental Biology; Disease; Diseases of signal transduction by growth factor receptors and second messengers; ERK/MAPK targets; ERKs are inactivated; ESR-mediated signaling; Estrogen-dependent nuclear events downstream of ESR-membrane signaling; Estrogen-stimulated signaling through PRKCZ; Extra-nuclear estrogen signaling; FCERI mediated MAPK activation; FCGR3A-mediated phagocytosis; Fc epsilon receptor (FCERI) signaling; Fcgamma receptor (FCGR) dependent phagocytosis; Formation of apoptosome; Frs2-mediated activation; G alpha (i) signalling events; G alpha (q) signalling events; G-protein mediated events; GPCR downstream signalling; Gastrin-CREB signalling pathway via PKC and MAPK; Gene expression (Transcription); Generic Transcription Pathway; Golgi Cisternae Pericentriolar Stack Reorganization; Growth hormone receptor signaling; Hemostasis; ISG15 antiviral mechanism; Immune System; Infection with Mycobacterium tuberculosis; Infectious disease; Innate Immune System; Insulin receptor signalling cascade; Interferon Signaling; Interleukin-17 signaling; Intracellular signaling by second messengers; Intrinsic Pathway for Apoptosis; L1CAM interactions; Leishmania infection; Leishmania phagocytosis; M Phase; MAP kinase activation; MAP2K and MAPK activation; MAPK family signaling cascades; MAPK targets/ Nuclear events mediated by MAP kinases; MAPK1 (ERK2) activation; MAPK1/MAPK3 signaling; MAPK3 (ERK1) activation; Mitotic Prophase; MyD88 cascade initiated on plasma membrane; MyD88 dependent cascade initiated on endosome; MyD88-independent TLR4 cascade; MyD88:MAL(TIRAP) cascade initiated on plasma membrane; NCAM signaling for neurite out-growth; Negative feedback regulation of MAPK pathway; Negative regulation of FGFR1 signaling; Negative regulation of FGFR2 signaling; Negative regulation of FGFR3 signaling; Negative regulation of FGFR4 signaling; Negative regulation of MAPK pathway; Negative regulation of the PI3K/AKT network; Nervous system development; Neuronal System; Neurotransmitter receptors and postsynaptic signal transmission; Neutrophil degranulation; Nuclear Events (kinase and transcription factor activation); Nuclear events stimulated by ALK signaling in cancer; Oncogene Induced Senescence; Oncogenic MAPK signaling; Opioid Signalling; Oxidative Stress Induced Senescence; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling; PIP3 activates AKT signaling; PLC beta mediated events; PTEN Regulation; Paradoxical activation of RAF signaling by kinase inactive BRAF; Parasite infection; Platelet activation, signaling and aggregation; Post NMDA receptor activation events; Programmed Cell Death; Prolonged ERK activation events; RAF-independent MAPK1/3 activation; RAF/MAP kinase cascade; RHO GTPase Effectors; RHO GTPases Activate NADPH Oxidases; RHO GTPases Activate WASPs and WAVEs; RNA Polymerase I Promoter Clearance; RNA Polymerase I Promoter Opening; RNA Polymerase I Transcription; RNA Polymerase II Transcription; RSK activation; RUNX2 regulates bone development; RUNX2 regulates osteoblast differentiation; Recycling pathway of L1; Regulation of HSF1-mediated heat shock response; Regulation of PTEN gene transcription; Regulation of actin dynamics for phagocytic cup formation; Regulation of the apoptosome activity; Response of Mtb to phagocytosis; Senescence-Associated Secretory Phenotype (SASP); Signal Transduction; Signal attenuation; Signal transduction by L1; Signaling by ALK fusions and activated point mutants; Signaling by ALK in cancer; Signaling by BRAF and RAF1 fusions; Signaling by FGFR; Signaling by FGFR1; Signaling by FGFR2; Signaling by FGFR3; Signaling by FGFR4; Signaling by GPCR; Signaling by Insulin receptor; Signaling by Interleukins; Signaling by MAP2K mutants; Signaling by MAPK mutants; Signaling by NTRK1 (TRKA); Signaling by NTRKs; Signaling by Nuclear Receptors; Signaling by RAF1 mutants; Signaling by RAS mutants; Signaling by Receptor Tyrosine Kinases; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Signaling by high-kinase activity BRAF mutants; Signaling by moderate kinase activity BRAF mutants; Signaling downstream of RAS mutants; Signalling to ERKs; Spry regulation of FGF signaling; Suppression of apoptosis; TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation; TRIF(TICAM1)-mediated TLR4 signaling; Thrombin signalling through proteinase activated receptors (PARs); Toll Like Receptor 10 (TLR10) Cascade; Toll Like Receptor 2 (TLR2) Cascade; Toll Like Receptor 3 (TLR3) Cascade; Toll Like Receptor 4 (TLR4) Cascade; Toll Like Receptor 5 (TLR5) Cascade; Toll Like Receptor 7/8 (TLR7/8) Cascade; Toll Like Receptor 9 (TLR9) Cascade; Toll Like Receptor TLR1:TLR2 Cascade; Toll Like Receptor TLR6:TLR2 Cascade; Toll-like Receptor Cascades; Transcriptional regulation by RUNX2; Transmission across Chemical Synapses; phospho-PLA2 pathway",TRUE
BRD-K02992638,HUVEC,trt_cp,up,0.2794291401281973,0.003138138634091873,0.007218380075991184,0.8828886363003924,NA,NA,0.8846923670506942,108,62,DCK,Nucleoside reverse transcriptase inhibitor,60825,lamivudine,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,JTEGQNOMFQHVDC-NKWVEPMBSA-N,NA,NA,NA,1,60825,CHEMBL141,33986,60825,DB00709,LAMIVUDINE,4,1,Small molecule,1995,1,0,0,1,0,1992,1,-vudine,"antineoplastics,antivirals (zidovudine group) (exception: edoxudine)",Antiviral,0,NA,NA,NA,NA,DNA inhibitor,INHIBITOR,1,1,1,"When monophosporylated is incorporates into the DNA, when triphosporylated inhibits the enzymes",NA,lamivudine,Nucleoside reverse transcriptase inhibitor,Nucleoside reverse transcriptase inhibitor; DNA inhibitor,DCK,1,FALSE,Metabolism; Metabolism of nucleotides; Nucleotide salvage; Purine salvage; Pyrimidine salvage,TRUE
BRD-K33106058,HUVEC,trt_cp,up,0.27776807173642815,0.0034055596325108907,0.00776725556070325,0.8776402988988674,NA,NA,0.8313845269327166,108,62,AICDA; BCR; CDA; DCK; NT5C; NT5C1A; NT5C1B-RDH14; NT5C2; NT5C3A; NT5C3B; NT5E; NT5M; POLA1; POLB; SLC28A1; SLC28A3; SLC29A1; SLC29A2; SLC29A3; ST6GAL1; UCK1; UCK2; UCKL1,Ribonucleotide reductase inhibitor,596,cytarabine,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,NA,POLA1; POLB,Ribonucleotide reductase inhibitor,0,596,CHEMBL78,6687,596,NA,NA,0,0,Small molecule,NA,0,0,0,-1,-1,NA,-1,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,cytarabine,Ribonucleotide reductase inhibitor,Ribonucleotide reductase inhibitor,POLA1; POLB; AICDA; BCR; CDA; DCK; NT5C; NT5C1A; NT5C1B-RDH14; NT5C2; NT5C3A; NT5C3B; NT5E; NT5M; SLC28A1; SLC28A3; SLC29A1; SLC29A2; SLC29A3; ST6GAL1; UCK1; UCK2; UCKL1,23,FALSE,"APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway; Abacavir metabolism; Abacavir transport and metabolism; Abasic sugar-phosphate removal via the single-nucleotide replacement pathway; Activation of the pre-replicative complex; Asparagine N-linked glycosylation; Base Excision Repair; Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein; CDC42 GTPase cycle; Cell Cycle; Cell Cycle, Mitotic; Cell recruitment (pro-inflammatory response); Chromosome Maintenance; DNA Repair; DNA Replication; DNA Replication Pre-Initiation; DNA replication initiation; DNA strand elongation; Deadenylation-dependent mRNA decay; Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS); Defective pyroptosis; Deubiquitination; Disease; Diseases of programmed cell death; Diseases of signal transduction by growth factor receptors and second messengers; Disorders of transmembrane transporters; E2F mediated regulation of DNA replication; Extension of Telomeres; FGFR1 mutant receptor activation; G1/S Transition; G1/S-Specific Transcription; Immune System; Infectious disease; Inhibition of replication initiation of damaged DNA by RB1/E2F1; Innate Immune System; Lagging Strand Synthesis; Leading Strand Synthesis; Leishmania infection; Maturation of protein 3a; Metabolism; Metabolism of RNA; Metabolism of nucleotides; Metabolism of proteins; Metabolism of vitamins and cofactors; Metabolism of water-soluble vitamins and cofactors; Mitotic G1 phase and G1/S transition; N-Glycan antennae elongation; N-glycan antennae elongation in the medial/trans-Golgi; Neutrophil degranulation; Nicotinate metabolism; Nucleobase catabolism; Nucleotide salvage; O-linked glycosylation; O-linked glycosylation of mucins; PCNA-Dependent Long Patch Base Excision Repair; POLB-Dependent Long Patch Base Excision Repair; Polymerase switching; Polymerase switching on the C-strand of the telomere; Post-translational protein modification; Processive synthesis on the lagging strand; Purine catabolism; Purine salvage; Purinergic signaling in leishmaniasis infection; Pyrimidine catabolism; Pyrimidine salvage; RAC1 GTPase cycle; RAC2 GTPase cycle; RAC3 GTPase cycle; RHO GTPase cycle; RHOA GTPase cycle; RHOB GTPase cycle; RHOC GTPase cycle; Removal of the Flap Intermediate; Resolution of AP sites via the multiple-nucleotide patch replacement pathway; Resolution of AP sites via the single-nucleotide replacement pathway; Resolution of Abasic Sites (AP sites); S Phase; SARS-CoV Infections; SARS-CoV-1 Infection; SARS-CoV-2 Infection; SLC transporter disorders; SLC-mediated transmembrane transport; Sialic acid metabolism; Signal Transduction; Signaling by FGFR in disease; Signaling by FGFR1 in disease; Signaling by Rho GTPases; Signaling by Rho GTPases, Miro GTPases and RHOBTB3; Signaling by cytosolic FGFR1 fusion mutants; Synthesis of DNA; Synthesis of substrates in N-glycan biosythesis; Telomere C-strand (Lagging Strand) Synthesis; Telomere C-strand synthesis initiation; Telomere Maintenance; Termination of O-glycan biosynthesis; Translation of Structural Proteins; Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane; Transport of small molecules; Transport of vitamins, nucleosides, and related molecules; Transport to the Golgi and subsequent modification; Ub-specific processing proteases; mRNA decay by 3' to 5' exoribonuclease",TRUE
BRD-K06294530,HUVEC,trt_cp,up,0.2614149148811664,0.012290029365828401,0.024752378529421352,0.8259706113762113,NA,NA,0.8853332187551489,108,62,NA,NA,NA,UK-383367,NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO,ARJCBSRIPGJMAD-LLVKDONJSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,UK-383367,NA,NA,NA,0,FALSE,NA,TRUE
BRD-K45152786,HUVEC,trt_cp,up,0.25984525605042974,0.01317621773056488,0.02636905380076677,0.82101109303861,NA,NA,0.8579786883490712,108,62,NA,NA,NA,merbarone,O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O,JARCFMKMOFFIGZ-UHFFFAOYSA-N,NA,TOP2A,Topoisomerase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,merbarone,NA,Topoisomerase inhibitor,TOP2A,1,FALSE,"Cell Cycle; Cell Cycle, Mitotic; G0 and Early G1; Metabolism of proteins; Mitotic G1 phase and G1/S transition; Post-translational protein modification; SUMO E3 ligases SUMOylate target proteins; SUMOylation; SUMOylation of DNA replication proteins; Transcription of E2F targets under negative control by DREAM complex",TRUE
BRD-K86892782,HUVEC,trt_cp,up,0.2523358426643043,0.022387075989210727,0.04272225641528376,0.7972842342691543,NA,NA,0.8300334798757382,108,62,NA,NA,NA,edoxudine,CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O,XACKNLSZYYIACO-DJLDLDEBSA-N,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,edoxudine,NA,NA,NA,0,FALSE,NA,TRUE
